.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 8,758,733

« Back to Dashboard

Claims for Patent: 8,758,733

Title:Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists
Abstract: The present invention is directed to compositions and methods for the treatment of post-chemotherapeutic hypotrichosis. More specifically, the present invention is directed to the use of compositions comprising bimatoprost for the treatment of post-chemotherapeutic hypotrichosis which may be applied before, during and after receiving chemotherapeutic treatment.
Inventor(s): Ahluwalia; Gurpreet (Orange, CA), Beddingfield; Frederick C. (Pacific Palisades, CA), Edwards; Sydney G. (Aliso Viejo, CA), Whitcup; Scott M. (Laguna Hills, CA)
Assignee: Allergan, Inc. (Irvine, CA)
Application Number:13/738,732
Patent Claims: 1. A method of growing eyelashes in chemotherapy patients, the method comprising applying 0.03% w/v bimatoprost to the eyelids of one selected from the group consisting of before, during, or after chemotherapeutic treatment.

2. The method of claim 1, wherein the 0.03% w/v bimatoprost is applied at least once a day after chemotherapeutic treatment.

3. The method of claim 2, wherein the method results in eyelashes which are longer or thicker or darker in comparison to the eyelashes of chemotherapy patients who did not receive 0.03% bimatoprost.

4. The method of claim 2, wherein the method is applied for at least 6 months after completing chemotherapeutic treatment.

5. The method of claim 4, wherein the method is applied for at least 12 months after completing chemotherapeutic treatment.

6. The method of claim 2, wherein the number or length of eyelashes increase in comparison to post-chemotherapeutic patients who did not receive 0.03% w/v bimatoprost.

7. The method of claim 1, wherein the bimatoprost is added during and after chemotherapeutic treatment.

8. The method of claim 2, wherein the method is applied twice a day.

9. The method of claim 8, wherein the bimatoprost is applied to the upper or lower eyelid margin of each eye.

10. The method of claim 2, wherein the method effectively treats post-chemotherapeutic hypotrichosis.

11. The method of claim 1, further comprising the step of administering one selected from the group consisting of Minoxidil.RTM. and Propecia.RTM..

12. The method of claim 1, wherein the method results in lower incidence of conjunctival hyperemia, punctate keratitis, erythema of the eyelid, eye pruritus and skin hyperpigmentation than in patients receiving 0.03% w/v bimatoprost for treatment of idiopathic hypotrichosis.

13. A method of treating loss of eyelashes in patients undergoing chemotherapy, the method comprising applying 0.03% w/v bimatoprost to the eyelids of one selected from the group consisting of before, during, and after chemotherapeutic treatment.

14. The method of claim 13, wherein the 0.03% bimatoprost is applied at least once a day.

15. The method of claim 14, wherein the method results in eyelashes which are longer or thicker or darker in comparison to the eyelashes of patients who did not receive 0.03% bimatoprost.

16. The method of claim 14, wherein the method is applied for at least 6 months after completing chemotherapeutic treatment.

17. The method of claim 14, wherein the method is applied for at least 12 months after completing chemotherapeutic treatment.

18. The method of claim 14 wherein the 0.03% w/v bimatoprost is applied once a day.

19. The method of claim 18 wherein the 0.03% w/v bimatoprost is applied to the upper eyelid.

20. The method of claim 18 wherein the 0.03% w/v bimatoprost is applied to the upper eyelid or the lower eyelid.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc